EISAI CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6,240 JPY | -0.30% |
|
+7.14% | -11.51% |
| Apr. 24 | Biogen beats quarterly profit estimates, Alzheimer's drug sales jump | RE |
| Apr. 23 | Alzheimer's drug adoption in US slowed by doctors' skepticism | RE |
| Sales 2024 * | 735B 4.69B | Sales 2025 * | 778B 4.96B | Capitalization | 1,795B 11.45B |
|---|---|---|---|---|---|
| Net income 2024 * | 41.04B 262M | Net income 2025 * | 49.92B 318M | EV / Sales 2024 * | 2.21 x |
| Net cash position 2024 * | 172B 1.1B | Net cash position 2025 * | 184B 1.17B | EV / Sales 2025 * | 2.07 x |
| P/E ratio 2024 * |
44
x | P/E ratio 2025 * |
36.1
x | Employees | 11,076 |
| Yield 2024 * |
2.59% | Yield 2025 * |
2.65% | Free-Float | 93.84% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eisai Co., Ltd.
More recommendations
More press releases
| 1 day | -0.30% | ||
| 1 week | +5.74% | ||
| Current month | +0.39% | ||
| 1 month | -1.81% | ||
| 3 months | -10.28% | ||
| 6 months | -23.34% | ||
| Current year | -11.51% |
1 week
5 923.00
6 333.00
1 month
5 795.006 426.00
Current year
5 795.007 818.00
1 year
5 795.0011 250.00
3 years
5 011.0012 765.00
5 years
5 011.0012 765.00
10 years
3 900.0012 765.00
| Managers | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Mitsuru Shomon
DFI | Director of Finance/CFO | - | - |
Makoto Hoketsu
CTO | Chief Tech/Sci/R&D Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Haruo Naito
CEO | Chief Executive Officer | 76 | 75-09-30 |
Fumihiko Ike
BRD | Director/Board Member | 71 | 21-05-31 |
Toru Moriyama
BRD | Director/Board Member | 69 | - |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 5.78% | 15 M€ | +7.34% | ||
| 1.23% | 251 M€ | +13.17% | ||
| 1.13% | 31,732 M€ | +14.31% | - | |
| 1.12% | 1,198 M€ | +13.48% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 6,240 | -0.30% | 1 179 200 |
| 24-04-25 | 6,259 | +2.79% | 2,587,700 |
| 24-04-24 | 6,089 | -0.02% | 1,168,700 |
| 24-04-23 | 6,090 | -0.03% | 641,600 |
| 24-04-22 | 6,092 | +3.24% | 1,002,400 |
Delayed Quote Japan Exchange, April 26, 2024 at 02:00 am EDT
More quotes
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).
Sector
Pharmaceuticals
Calendar
2024-05-14
- Q4 2023 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
6,259
JPY
Average target price
8,193
JPY
Spread / Average Target
+30.90%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.51% | 11.54B | |
| +25.11% | 556B | |
| -6.33% | 354B | |
| +19.90% | 331B | |
| +7.95% | 296B | |
| +12.68% | 233B | |
| +5.27% | 201B | |
| -10.31% | 193B | |
| -12.26% | 143B | |
| -6.47% | 144B |
- Stock Market
- Equities
- 4523 Stock
